



A P P L I C A T I O N

for

UNITED STATES LETTERS PATENT

on

METHODS OF IDENTIFYING OPTIMAL DRUG COMBINATIONS AND  
COMPOSITIONS THEREOF

by

Dale R. Pfost

Sheets of Drawings: 7

Docket No.: P-OD 5078

Attorneys  
CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive, 7th Floor  
San Diego, California 92122  
USPTO Customer No. 23601



METHODS OF IDENTIFYING OPTIMAL DRUG COMBINATIONS AND  
COMPOSITIONS THEREOF

5

BACKGROUND INFORMATION

This application claims the benefit of U.S. Provisional Application No. 60/167,931, filed November 29, 1999, which is incorporated herein by reference.

The invention relates to compositions for  
10 effectively treating a population of patients having a pathology, and more specifically to compositions directed to effectively treat patients with a plurality of genetic profiles.

It has long been known that a pharmaceutical  
15 compound can be effective in treating certain patients afflicted with a pathology while being ineffective in treating other patients afflicted with the same pathology. Similarly, some patients with a pathology can experience adverse drug reactions as a result of the  
20 toxicity of the drug to those individuals, while others do not.

To improve the likelihood of effectively treating an individual, clinicians often simultaneously administer a variety of pharmaceutical compounds.  
25 Unfortunately, these pharmaceutical compounds often have very similar behavior and are not significantly more effective than any single compound, while potentially increasing the toxic effects experienced by the individual.

Accordingly, a need exists for novel compositions of pharmaceutical compounds which increase the likelihood of effectively treating an individual without resulting in toxic effects. The present invention satisfies this need and provides related advantages as well.

#### SUMMARY OF THE INVENTION

The invention provides a composition of compounds effective for treating a pathology, the composition comprising at least two compounds that modulate the activity of one or more target molecules associated with one or more Single Nucleotide Polymorphisms (SNPs). The invention also provides methods of increasing overall treatment efficacy for a population of patients having a pathology, by analyzing compounds for efficacy correlated with the presence of a SNP associated with the target molecule and by selecting a combination of at least two of the compounds that exhibit the highest overall mean response of all dosing options in the population of patients.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the response of patients having five different genotypes to different amounts of drug A, as described in Example I.

Figure 2 shows the response of patients having five different genotypes to different amounts of drug B, as described in Example I.

Figure 3 shows the response of patients having five different genotypes to different amounts of drug C, as described in Example I.

Figure 4 shows the response of patients having  
5 five different genotypes to different amounts of drug D, as described in Example I.

Figure 5 shows the response of patients having five different genotypes to different amounts of drug E, as described in Example I.

10 Figure 6 shows the dose-response relationships of drug A in populations consisting of two genetic variants, as described in Example II.

Figure 7 shows the dose-response relationships of drug B in populations consisting of two genetic  
15 variants, as described in Example II.

#### DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided compositions of compounds effective for treating a pathology, said composition comprising at  
20 least two compounds that modulate the activity of one or more target molecules associated with one or more Single Nucleotide Polymorphisms (SNPs), wherein each compound modulates the activity of at least one target molecule associated with one or more SNPs, and wherein said  
25 combination is effective for at least one patient having said pathology.

An invention composition increases the percentage of a patient population with a particular pathology that can be effectively treated relative to the use of individual compounds or relative to the use of known combinations of compounds on that population. The increased efficacy of the composition is achieved by combining compounds according to the efficacy of each compound for treating various subpopulations of patients with a pathology, in which each subpopulation has a unique set of genetic variations. Each subpopulation will typically have a unique characteristic response to therapeutic compounds. Knowledge of the efficacies of two or more compounds in treating patients with different genetic variations provides the opportunity to select the combination of compounds effective in treating a large percentage of the total population of patients while maintaining little or no toxicity.

The composition of the invention will comprise two or more compounds used to treat a pathology. Specifically, the phrase "two or more compounds" refers to a composition containing two, three, four, five, six, seven, eight, nine, ten or more compounds therein. As used herein, the term "compound" refers to a pharmaceutically active agent used to effect a physiological change in treating a pathology. Exemplary compounds can be chosen from drugs, pharmaceutically active natural products or dietary supplements, or any other type of compound (i.e., agent) useful in treating a pathology. Preferably, one or more of the compounds in the composition will be targeted toward treating a subset of the total population of patients with a pathology, in which the constituents of this subset have related or

identical genetic profiles. A compound targeted toward such a subset of the total population refers to a compound directed to modulating the activity of one or more target molecules that play a role in the pathology, wherein the one or more target molecules are associated with one or more genetic variations characteristic of that subset of the population. Such a target molecule may play a role in the symptoms, etiology, side-effects, progression of treatment, and the like, of a pathology.

- 10 An invention composition of compounds preferably comprises specific amounts of two or more compounds, combined for the purpose of effectively treating an optimum percentage of patients with a pathology while maintaining little or no toxicity. Since  
 15 a variety of different genetic variations can be associated with a single pathology, a composition can also include a combination of at least three compounds, a combination of at least four compounds, a combination of at least five compounds, a combination of at least six  
 20 compounds, a combination of at least seven compounds, a combination of at least eight compounds, a combination of at least nine compounds, a combination of at least ten or more compounds, and the like. The amount of each compound used per dosage in an invention composition can  
 25 vary from approximately 100 pg up to about 1 g (e.g., 100 pg, 1 ng, 10 ng, 100 ng or 1 mg, to 1 mg, 10 mg, 100 mg or 1 g, and the like).

- As used herein, the phrase "effective against" refers to the effective exposure or contacting of a  
 30 target molecule, or a cell or organism containing a target molecule, to a compound, such that such exposure

or contacting is correlated with modulating the activity of the target molecule. This modulated activity will result in at least partial treatment of a pathology by, for example, alleviating symptoms of the pathology, 5 treating the cause of the pathology, treating complications associated with a pathology, or otherwise effecting the treatment of a pathology, and the like. A compound of an invention composition can modulate the activity of a target molecule by, for example, increasing 10 or decreasing enzymatic activity, increasing or decreasing gene expression, increasing or decreasing protein-protein interactions, increasing or decreasing signal transduction, increasing or decreasing transport or translocation across membranes, and the like. While a 15 compound of an invention composition can modulate the activity of a target molecule by directly contacting the target molecule, it is also contemplated that a compound can also indirectly modulate the activity of a target molecule by contacting a different molecule that effects 20 the activity of the target molecule.

The term "target molecule" refers to the molecule whose activity is modulated by a compound of the invention composition in the therapeutic action of the compound. A target molecule can vary from as large as an 25 association of molecules, such as a ribosome or a lipid bilayer, to as small as a small molecule or an ion, such as a hormone, cytokine, cAMP, NO,  $Ca^{2+}$ ,  $K^+$ , phosphate, and the like. An exemplary target molecule may be any molecule: (a) whose activity is modulated by the intended 30 pharmacodynamic action of the compound; (b) involved in the absorption of a compound; (c) involved in the distribution of a compound within an organism, organ,

tissue or cell; (d) involved in the biotransformation of a compound, such as the activation, degradation, and the like of a compound; or (e) involved in the excretion of a compound and/or metabolites of a compound. Typically, 5 this target molecule will be a biological macromolecule, such as RNA, DNA or a protein. In one embodiment, a preferred target molecule is a protein. Preferably, a target molecule is a protein whose activity is modulated by a compound in the intended pharmacodynamic action of 10 the compound.

A compound that is effective against a target molecule associated with one or more particular genetic variations refers to the ability of a compound to modulate the activity of a target molecule that plays a 15 role in the symptoms, etiology, complications or treatment of a pathology. Preferably, a compound modulates the activity of a target-protein associated with one or more genetic variations that plays a role in the symptoms, etiology, complications or treatment of a 20 pathology. For example, a protease normally having a glutamate at a position near the active site can have increased proteolytic activity as a result of a single nucleotide polymorphism arising in which the glutamate is changed to alanine (by, for example, an A→C nucleotide 25 polymorphism), resulting in this single nucleotide polymorphism playing a role in a pathology caused by increased proteolytic activity. A compound, such as a protease inhibitor, can be effective against a protease associated with this single nucleotide polymorphism by 30 inhibiting the proteolytic activity of the protease.



As used herein, a "genetic variation" refers to any deletion, insertion or base substitution of the genomic DNA of one or more individuals in a first portion of a total population which thereby results in a difference at the site of the deletion, insertion or base substitution relative to one or more individuals in a second portion of the total population. Thus, the term "genetic variation" encompasses "wild type" or the most frequently occurring variation, and also includes "mutant," or the less frequently occurring variation. A preferred type of genetic variation is a single nucleotide polymorphism, or SNP. As used herein, a SNP refers to a genetic variation at a specific site in the genome of an organism, where the nucleotide identity at that site varies between genomic allelic members of a population of organisms. In one embodiment of the present invention, a genetic variation or a SNP that is correlated with a particular pathology is known to effect: an individual's predisposition to acquire that pathology; the severity of the pathology in an individual; an individual's response to therapeutic treatment of that pathology; and the like. Typically, the efficacy and/or toxicity of a compound is correlated with one or more genetic variations or SNPs or the expression of one or more SNPs. Accordingly, it is contemplated herein that a compound interacts with a target molecule at a position on the target molecule corresponding to one or more SNPs, or the expression of one or more SNPs. Preferably, the mechanism of action of a compound on a target molecule having one or more genetic variations or SNPs is known.

As used herein, a target molecule that is "associated with" or "correlates with" a particular genetic variation, preferably a particular SNP, is a molecule that can be functionally distinguished in its structure, activity, concentration, compartmentalization, degradation, secretion, and the like, as a result of such genetic variation.

In a particular pathology, it is contemplated herein that one or more genetic variations, preferably one or more SNPs, can be correlated with the symptoms, etiology, side-effects or progression of treatment of that pathology. Additionally, one or more genetic variations can be correlated with the efficacy, or toxicity, or both, of a compound used for treating the pathology. As used herein, the "correlation of a genetic variation with a pathology" refers to the increased occurrence of the pathology in a first portion of a total population having a particular genetic variation relative to a second portion of a total population having a second genetic variation. As used herein the "correlation of a genetic variation with effective treatment" of a pathology refers to an increased efficacy of treatment of the pathology in a first portion of a total population having a particular genetic variation relative to a second portion of a total population having a second genetic variation. Patients with a particular pathology can have a wide variety of one or more genetic variations, all of which are correlated with that pathology. A particular combination of genetic variations correlated with a pathology or the treatment of the pathology is referred to as a genetic profile or a genotype. Thus, a patient or group of patients with a

pathology that have the same combination of genetic variations correlated to that pathology can be characterized as having a particular genetic profile.

- In addition, a patient or group of patients
- 5 with a particular pathology that have similar combinations of genetic variations can be characterized as having a similar genetic profile. As used herein, a group of patients with a "similar genetic profile" refers to a group of patients where each member of the group has
- 10 at least 50% of the same genetic variations correlated to a particular pathology as every other member of the group. Preferably, a group of patients with a similar genetic profile has at least 60% of the same genetic variations as every other member of the group. More
- 15 preferably, a group of patients with a similar genetic profile has at least 75% of the same genetic variations as every other member of the group. Most preferably, a group of patients with a similar genetic profile has at least 90% of the same genetic variations as every other
- 20 member of the group.

- A genetic variation, such as a SNP, can be identified by finding a difference in the nucleotide sequence of an individual compared to the most common nucleotide sequence of the overall population. Methods
- 25 used to identify genetic variations, such as SNPs, are well known in the art and include hybridization stability methods such as SSCP, where the hybrids are identified, for example, by electrophoretic analysis, denaturing HPLC (U.S. Patent No. 5,795,976), or addressable DNA array
- 30 hybridization (U.S. Patent No. 5,547,839). The perturbation resulting from the hybrid instability can be

exploited to detect SNPs by its impact on enzymatic reactions such as restriction endonucleases (RFLP) (U.S. Patent No. 4,623,619), allele-specific oligonucleotide ligation (U.S. Patent No. 4,988,617), allele-specific cleavage (U.S. Patent No. 5,422,253), allele-specific PCR (U.S. Patent No. 4,683,195), and allele-specific LCR (U.S. Patent No. 5,494,810). Other methods for detecting SNP genetic variations use polymerase-dependent primer extension techniques such as GBA which uses single nucleotide extension (U.S. Patent No. 5,888,819) or limited extension from a specific primer for analysis by, for example, mass spectrometry (U.S. Patent No. 5,547,835). Correlation of data to identify a site of a genetic variation such as a SNP can be carried out by sequence comparison of the results of the above experiments for multiple individuals (Nickerson et al., Nucleic Acids Res 25:2745-2751 (1997), U.S. Patent No. 5,762,876).

In accordance with the present invention, certain genetic variations are correlated with a pathology or treatment of a pathology. For example, the SNP encoding the change from normal hemoglobin to sickle hemoglobin in sickle cell anemia. Methods for using a variety of patient determinants such as genetic variations to establish if one or more determinants are correlated with a pathology, or if one or more determinants are correlated with treatment of a pathology are known in the art and are exemplified in U.S. Patent No. 5,860,917 and in publications such as WO 97/13875, WO 97/21833, WO 99/11822, WO 99/24571, each of which is incorporated herein by reference.

In addition to genetic variations in a patient population, it is also contemplated herein that other determinants such as diet, exercise, smoking, prior medical history, and the like, can also be correlated to a pathology or treatment of a pathology by a compound of the invention. These further determinants are particularly useful when used in concert with one or more genetic variants in finding the correlation of such determinants with a pathology or treatment of a pathology.

A compound that is "stably effective" for a particular percentage of a total patient population is a compound for which the effectiveness does not change over a time scale of 1, 2, 5, 10, 25, 50 or 100 years. For example, a therapeutic compound used to treat a viral pathology will often lose its effectiveness after a few years as a result of the evolutionary changes undergone in the viral genome, and thus will typically not be stably effective. However, a pathology such as a human genetic disorder, does not change quickly over time. Therefore, a compound effective for treating such a genetic disorder will be effective over a long period of time, and thus is considered stably effective in treating that pathology.

As used herein, a total patient population is a group of patients which each have a particular pathology. For example, a total patient population can be all patients having glaucoma. In addition, a total patient population can be a subset of a larger population of patients. For example, a subset population of glaucoma patients can be all patients suffering from pigmentary

glaucoma. In this case, the total patient population is a population in which each patient has pigmentary glaucoma. Thus a total patient population can be any group of patients having a common pathology, or further  
5 can be any group of patients having a common pathology and also having similar or identical symptoms, diagnostic markers, medical history, genetic profile, or the like.

The composition of the invention will be effective for at least one patient having a particular  
10 pathology. Preferably, the composition of the invention is effective for at least 1% of a subset of the total patient population, where the subset population is defined as a group of patients smaller than the total population and the members of the subset population have  
15 similar or identical symptoms, diagnostic markers, medical history, genetic profile, or the like.

In one embodiment of the invention, the composition is effective for a greater percentage of the total patient population than any single compound.  
20 Typically, such a composition is effective for at least 10%, 15%, 20%, or 25% of the total patient population. Preferably, the composition is effective for at least 50% of the total patient population. More preferably, the composition is effective for at least 75% of the total  
25 patient population. Most preferably, the composition is effective for at least 90% of the total patient population.

The percentage of the total patient population for which an invention composition is effective can be  
30 calculated. Typically, the first step in calculating the

percent efficacy of a composition is determining the percentage of each subpopulation (i.e., group of patients having the same genetic profile) for which a particular amount of each compound of the invention composition is effective per dose. Next, the percent efficacy of a composition of two or more compounds is determined for each subpopulation. Finally, the percent efficacies for all subpopulations are combined to result in an overall percent efficacy for the total patient population.

Calculation of the percentage of a subpopulation for which a particular amount of a compound is effective per dose is carried out by correlating the efficacy of one or more particular amounts of that compound in treating a particular percentage of one or more subpopulations of a patient population. In one embodiment, this calculation includes consideration of the amount of compound necessary to produce a therapeutic effect, as described by the  $ED_{50}$ . As used herein,  $ED_{50}$  refers to the dosage Effective Dosage to treat 50% of patients having a particular genetic profile. Thus a therapeutic compound effective against a pathology only for a subpopulation of patients with a particular genetic profile which make up 20% of the total patient population will be effective for 10% of the total patient population when administered at a dosage level of  $ED_{50}=1$ .

In one embodiment of the invention, the level of efficacy of a compound for a subpopulation of the total patient population is determined by the one or more target molecules (e.g., one or more target-proteins) against which the compound is effective, and by the genetic variations that are correlated with the efficacy

of the compound against the one or more target molecules. Typically, a compound will be more effective for at least one subpopulation than for at least one other subpopulation. For example, a particular compound may be highly effective against a target molecule in a subpopulation of patients having a particular genetic profile, while that compound may be ineffective against that target molecule in any other subpopulation of patients having a different genetic profile.

10 A therapeutic compound that causes a toxic reaction in patients with a particular pathology is characterized as toxic for a particular percentage of the total patient population. The percentage of the total patient population for which a therapeutic compound is  
15 toxic per dose is typically determined by the amount of the compound necessary to produce a toxic effect for each subpopulation, having a particular genetic profile, of the total patient population.

In another embodiment of the invention, a  
20 composition of compounds is provided which is targeted against at least one target molecule associated with a pathology, the composition comprising at least two compounds that each are effective against at least one genetic variation associated with the target molecule(s),  
25 in which the combination is stably effective for at least one patient having the pathology. In this embodiment, it is possible for each compound to be effective against the same genetic variation within the same target molecule, while the efficacy of each compound against that genetic  
30 variation can be the same or can be different. It is also within the scope of this embodiment that each



compound is effective against mutually exclusive genetic variations (e.g., SNPs) within the same target molecule. For example, a first compound can be effective against a SNP in the active site of a protein by acting as an enzymatic inhibitor, while a second compound, such as a monoclonal antibody, can be effective against a surface-residue SNP on the same protein. In both of the above possibilities, two or more compounds effective against genetic variation(s) of a single target molecule allow the two or more compounds to have complementary efficacies against the same protein, thus resulting in an increased efficacy against the target molecule, relative to the efficacy of any single compound.

It is also within the scope of this embodiment that the composition of two or more compounds is effective against genetic variations associated with at least two target molecules. For example, in an apoptotic disease involving an altered level of activation of a caspase by a cytokine, a first compound can be effective against a SNP of the cytokine receptor, while a second compound can be effective against a SNP of the caspase. A combination of these two compounds will therefore be effective for a combination of the populations for which each single compound is effective. Further, the invention composition of two or more compounds can be effective against at least one, at least two, at least three or more of these target molecules, each of which are associated with at least two genetic variations.

In yet another embodiment of the invention, an invention composition of compounds is provided in which the efficacies of the compounds are correlated with

modulating the activity of a single target-protein associated with a pathology. This particular invention composition comprises at least two compounds that are effective in treating patients having one or more SNPs within the target-protein, wherein the combination is effective for at least one patient having said pathology. In this embodiment, each compound can be effective in treating patients having the same SNP associated with a single target molecule, or each compound can be effective in treating patients having mutually exclusive SNPs associated with a single target protein.

Thus, for a pathology in which one protein associated with the pathology can be one of a plurality of different genetic variants, a composition of the invention can be directed toward treating the various groups of patients having these different variants. For example, three different forms of the  $\beta$ -adrenergic receptor can exist in patients who have suffered congestive heart failure. A composition of the invention can comprise three compounds that block  $\beta$ -adrenergic receptor activity ( $\beta$ -blockers), in which each compound is effective for a different form of the  $\beta$ -adrenergic receptor.

In another embodiment of the invention, a method is provided for increasing treatment efficacy for a given population of patients having a pathology, comprising:

(a) analyzing compounds known or suspected of acting on at least one target-protein corresponding to the pathology for efficacy correlated with the presence of a genetic variation on the target protein(s); and

(b) selecting, for treatment of the patients, a combination of at least two of the compounds that exhibits the highest overall mean response in treating the population of patients.

10 As used herein, the phrase "increasing treatment efficacy" or "increasing treatment coverage" and grammatical variants thereof, refers to increasing the percentage of a given population of patients having a pathology for which a combination of compounds is  
15 effective. A method of increasing treatment efficacy will be influenced by a variety of factors. The principle factors determining the treatment efficacy by a particular composition of two or more compounds are: percentage of coverage by each individual compound,  
20 interaction (e.g., drug overlap) between different compounds in a composition, and toxicity restrictions.

As discussed herein above, compounds known or suspected of modulating the activity of at least one  
25 target molecule can be analyzed for the correlation of the efficacy of the compound with one or more genetic variations in patients with a pathology. This efficacy can be represented as the percentage of therapeutic coverage (i.e., therapeutic effectiveness) for particular compound, which is determined by the percentage of  
30 therapeutic coverage of each of the subpopulations of a

patient population in conjunction with the amount of the compound present per dose of the combination.

Once the treatment efficacies of two or more individual compounds have been correlated with different genetic variations (e.g., SNPs), a combination of compounds can then be selected according to the desired treatment efficacy of a patient population that is achieved by such a combination of the therapeutic compounds.

Overall treatment efficacy of a patient population by an invention composition will be affected by the interaction of the two or more compounds in the composition. For example, if two compounds which are directed to the same target molecule and are effective against the same SNPs of the target molecule in the same way, a considerable amount of drug overlap can result. Complete drug overlap, as opposed to partial drug overlap, will limit the extent of increased treatment efficacy resultant from combining two compounds, as the efficacy of the combination of compounds can represent no more than the coverage provided by one of the compounds.

Alternatively, a combination of compounds in which each compound is independently effective against a different genetic variation can result in the efficacy of the combination being equal to the sum of the efficacies of the individual compounds. For example, in the simple case in which all patients with a particular pathology have one of two SNPs, a particular amount of a first compound is effective for 90% of a first subpopulation forming 50% of the total patient population, is combined

with a second compound effective for 60% of a second subpopulation forming the other 50% of the total patient population, the treatment efficacy for of the total patient population will be 75% ( $50\% \times 90\% + 50\% \times 60\%$ ). In such an example, whereas neither compound is effective for even half of the total patient population individually, a combination of the two compounds is effective for a majority of the total patient population.

The efficacy of a combination of compounds can also be greater than the sum of individual efficacies. For example, patients with a particular pathology can have either one or two SNPs, and the total patient population is distributed in such a way that 33% of the total patient population has a first SNP, 33% of the total patient population has a second SNP, and 33% of the total patient population has both the first and second SNPs. If a first compound is effective for 90% of the total patient population having the only the first SNP, and a second compound is effective for 60% of the total patient population having the only the second SNP, the summed efficacy would be 50% ( $33\% \times 90\% + 33\% \times 60\%$ ). However, the combination, being also effective against the population having both SNPs, would have an efficacy of 68% ( $33\% \times 90\% + 33\% \times 60\% + 33\% \times 60\% \times 90\%$ ).

In addition to relationships described hereinabove for interaction between compounds effective against genetic variations when used in combination, those of skill in the art will recognize that other relationships exist which can result in a variety of effects when combined, such as: two or more compounds being effective against a particular genetic profile or

subpopulation of patients against which no compound is individually effective; two or more compounds having partial overlap between subpopulations; a first compound enhancing the efficacy of a second compound against a particular subpopulation against which the first compound alone has no efficacy and the second compound alone has relatively low efficacy; and the like.

Irrespective of the particular mechanism involved, two or more compounds will have a relationship that is either: 1) completely overlapping, resulting in no increased or decreased efficacy relative to one or more compounds in the composition; 2) independent, resulting in additive efficacies in the composition; 3) partially overlapping, resulting in some additive effect, but less than that observed in the independent relationship; 4) canceling, resulting in efficacy below that of at least one compound in the composition; or 5) enhancing or synergistic, resulting in an efficacy of the composition being greater than the sum of the efficacies of each compound in the composition.

Toxicity will also influence treatment coverage by a particular composition of two or more compounds. While each compound will have a corresponding level of toxicity when individually administered to a patient, combinations of compounds can have toxicity interactions in a manner similar to combinations of compounds having efficacy interactions, resulting in different toxicities for different combinations of compounds. These toxicity relationships can be overlapping, independent, enhancing or canceling. However, for compound toxicity, an overlapping relationship will result in additive

toxicities of the individual compounds, while independent relationship will result in no additive or decreased toxicity relative to the individual compounds.

Typically, the relationship between toxicities of two or  
 5 more compounds will be overlapping or additive, as determined by summing the percentages of threshold level of toxicity for each compound for a single dose. For example, if a first compound has a threshold toxicity of 100 mg, and a single dose has 10 mg of this compound, the  
 10 dosage of this compound is 10% threshold toxicity. If the first compound is in a composition with 10 mg of a second compound, where the second compound has a threshold toxicity of 20 mg (the second compound therefore being at 50% toxicity), the total toxicity for  
 15 the composition will be 60% threshold toxicity (10% + 50%).

Non-interacting toxicities will not be additive, but considered separately. Thus a composition of two compounds, each administered at 90% individual  
 20 threshold toxicity, is not above threshold toxicity since neither compound is toxic on its own, nor does either compound add to the toxicity of the other. Toxicities that enhance one another will result in an overall toxicity higher than expected by summing the individual  
 25 toxicities. Toxicities that cancel one another will result in an overall toxicity lower than expected from the toxicity of one or more individual compounds.

In a specific embodiment of the invention, the toxicity of a compound or of a composition of two or more  
 30 compounds is different for different subpopulations within a population of patients. In this instance, a

step of formulating a composition that has little or no toxicity for the entire population includes determining the toxicity of a composition for each different subpopulation. Particular subpopulations, for example, 5 can have a genetic variation (e.g., a SNP) in an enzyme used for breaking down one or more compounds in the composition, this genetic variation resulting in modulated toxicity relative to the subpopulations that do not have this genetic variation.

10 As used herein, "toxicity" and grammatical variants thereof refers to a harmful effect caused by a compound in a role other than its intended pharmaceutical role, resulting in discomfort or endangerment of the patient. Typically a toxic effect of a compound will 15 cause necrosis or other permanent or irreversible damage to a patient. The dosage level considered to be minimally toxic or to have no toxicity is a dosage level that is not toxic to even a single member a total population of patients. A dosage level of a compound 20 having threshold toxicity is considered a dosage level at which the compound is toxic to at most 10% of a population, or alternatively is considered a dosage level at which a 20% increase in dosage level results in a 2-fold increase in the percent of a population for which 25 the compound is toxic. Preferably, a compound will be administered at a dosage level that is toxic to less than 5% of a total patient population and, more preferably, less than 1% of a total patient population.

Methods are known for analyzing compounds known 30 or suspected of acting on at least one target molecule corresponding to the pathology for efficacy correlated



with the presence of a genetic variation associated with a target molecule. Analysis of compounds for their ability to act on a target molecule can be carried out using a wide variety of methods, including *in vivo*, *in vitro* and *in situ* binding and/or inhibition assays, *in vivo* survival assays, clinical trials, and any other method useful to correlate the ability of a compound to modulate the activity of a target molecule (see, for example, Current Protocols in Molecular Biology (John Wiley and Sons, NY), which is incorporated herein by reference). A compound found to modulate the activity of a target molecule can then be further tested to determine the efficacy of this compound in treating a pathology in each subpopulation of a patient population. Such testing methods can be carried out using suitable animal models, or clinical trials. Similarly, such a compound can be tested to determine its toxicity in the various subpopulations of a patient population.

The process of selecting a combination of two or more compounds from all dosing options to optimize therapeutic coverage of the total patient population preferably includes: selection of combinations of compounds that are effective for a large percentage of a patient population, such as a combination having the highest overall mean response; and selection of combinations that have little or no toxicity for all of the total patient population. Suitable combinations of compounds will be combinations which are effective for one patient, at least 1% of the total patient population, at least 5%, 10%, 15%, 20%, at least 25% of the total patient population, preferably effective for at least 50% of the total patient population, more preferably

effective for at least 75% of the total patient population, most preferably for at least 90%, 95% or 98% of the total patient population. Typically, the combination selected will be effective against the maximum percentage of the total patient population while maintaining little or no toxicity.

The term "highest overall mean response" refers to the combination of compounds which have the highest percent efficacy for a total patient population.

- 10 Typically, a combination with the highest overall mean response is above threshold toxicity for no more than 25% of a total patient population, preferably less than 15% of a total patient population, more preferably less than 10% of a total patient population, even more preferably
- 15 less than 5% of a total patient population, most preferably no more than 1% of a total patient population. It is also contemplated herein that an invention composition will not have any toxicity for any portion of the patient population (e.g. 0% toxicity).

- 20 In accordance with another embodiment of the present invention, there are provided methods of determining a composition that has the highest mean response for a group of patients representing less than the total population. Such a sub-population may be a
- 25 single patient, or may be a group of patients with identical or similar genetic profile, or may be several groups of patients with identical or similar genetic profiles.

In another embodiment of the invention, a method is provided for maximizing overall population treatment efficacy of treatment for a particular pathology, comprising:

- 5 (a) determining the efficacies of a plurality of compounds known or suspected of treating said pathology;
- (b) determining the toxicity of said plurality of compounds; and
- 10 (c) selecting from said plurality of compounds a combination of compounds that is minimally toxic and is stably effective for at least one patient having said pathology.

Another embodiment of the invention provides a  
15 genotypically-facilitated method of treating a patient having a pathology comprising:

- (a) analyzing a therapeutic target molecule in a population of patients having said pathology to detect genetic variations, preferably SNPs, associated therewith;
- 20 (b) selecting a plurality of compounds having therapeutic efficacies correlated with the presence of at least one genetic variation associated with a target-protein; and
- 25 (c) administering said plurality of compounds to said patient;

wherein said combination is effective for at least one patient having said pathology.

The step of administering a plurality of compounds to a patient is carried out by any of a variety of methods known in the art. For example, it is within the scope of this invention that the plurality of compounds are administered to a patient as a pill, inhalant, topical application, suppository, by intravenous infusion, or any other mode well-known in the art for introducing a therapeutic compound or composition to a patient.

The step of administering a plurality of compounds can be carried out in such a way that two or more compounds are administered simultaneously, either in a single pharmaceutical composition of two or more compounds or as two or more separate pharmaceutical compositions of two or more compounds. It is further within the scope of the invention that the plurality of compounds are administered to a patient proximately. By "proximate administration" of a plurality of compounds and grammatic variants thereof is meant administration of at least two of a plurality of compounds non-simultaneously, but in close temporal proximity. For example, a first compound can be administered to a patient to reduce the swelling in a joint, followed by the administration of a second compound to reduce cytokine activity in the joint, and the like.

Typically, two or more compounds so administered proximately will be administered within 72 hours of each other. Preferably, such compounds will be

administered within 24 hours of each other. More preferably, such compounds will be administered within 6 hours of each other. Most preferably, such compounds will be administered within 1 hour of each other.

5            Provided in a further embodiment of the invention is a method of formulating a pharmaceutical composition for treating a particular pathology in a population of patients having said pathology, comprising:

10            (a) measuring a correlation of genetic variation of a target molecule in said population with patient response to at least one compound known or suspected to treat said pathology; and

15            (b) selecting at least two compounds that provide the greatest percentage of efficacy in said patient population, wherein said percentage is at least 1% of patients having said pathology.

Percentages of efficacy also contemplated herein include  
20 is at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 50%, at least 75%, at least 90%, at least 95% or at least 98%.

Another embodiment of the invention provides a method of formulating a therapeutic composition to treat  
25 a pathology in a population of patients having the pathology, comprising:

(a) analyzing a target molecule in a patient population to detect one or more genetic variations, preferably SNPs, associated therewith; and

- 5 (b) selecting a plurality of compounds having therapeutic efficacies correlated with the presence of at least one genetic variation associated with the target molecule, wherein said plurality is effective for at least one  
10 patient having said pathology.

- A formulated composition of the invention will be a combination of two or more selected compounds, specifying the amount of each selected compound, to be used per dose. This composition will typically be  
15 formulated such that it is either: effective for a maximum percentage of a total patient population; or exhibits the lowest variation in efficacy across different subpopulations of patients having the same genetic profile (e.g. an SNP profile); or both.

- 20 A composition that exhibits the lowest variation in efficacy across different subpopulations of patients having the same genetic profile (e.g., a SNP profile, and the like) refers to a composition that most closely approaches having equal efficacy for each patient  
25 subpopulation. For example, a first composition that is effective for 75% of a first subpopulation and effective for 65% of a second subpopulation exhibits a lower variation than a second composition that is effective for 95% of a first subpopulation and 45% of a second  
30 subpopulation. In the above example, if the two

10001301 010000

subpopulations represent 50% of the total patient population, the first and second compositions will be effective for the same overall percentage of the total patient population, but the first composition can be a  
5 preferred composition when it is desired to formulate the invention composition to have the lowest variation across different subpopulations.

In a further embodiment of the invention, a method is provided for minimizing the toxicity of a  
10 combination of compounds effective in treating a pathology. It is within the scope of the invention that a plurality of combinations of compounds can have overall mean efficacies within 25% or within 10% of each other, while the toxicities of such combinations can vary by  
15 more than 10% or more than 20%. When such a plurality of combinations exist, a combination which has the lowest toxicity can be preferred in favor of another combination which has a higher overall mean efficacy.

A composition of the invention comprises two or  
20 more compounds effective for at least one patient having a pathology. In addition to compounds effective for at least one patient having a pathology, a composition can also comprise a pharmaceutically acceptable carrier.

As used herein, the terms "pharmaceutically  
25 acceptable", "physiologically compatible" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to a mammal without the production of  
30 undesirable physiological effects such as nausea,

dizziness, gastric upset, and the like. Examples of pharmaceutically acceptable carriers are phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents

The preparation of a composition that contains active ingredients dissolved or dispersed therein is well known in the art. Typically such compositions are prepared as injectables either as liquid solutions or suspensions; however, solid forms suitable for solution, or suspension, in liquid prior to use can also be prepared. The preparation can also be emulsified.

The active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, as well as combinations of any two or more thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like, which enhance the effectiveness of the active ingredient.

The therapeutic composition of the present invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable nontoxic salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, perchloric acid,



- nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid,
- 5 cinnamic acid, naphthalene sulfonic acid, sulfanilic acid, and the like.

- Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium hydroxide, ammonium hydroxide, potassium
- 10 hydroxide, and the like; and organic bases such as mono-, di-, and tri-alkyl and -aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine, and the like) and optionally substituted ethanolamines (e.g., ethanolamine, diethanolamine, and the like).

- 15 Physiologically tolerable carriers are well known in the art. Exemplary liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH,
- 20 physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.

- 25 Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary additional liquid phases include glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.

In another embodiment of the invention, a method is provided for preparing a combination of compounds for treating one or more patients having a pathology, wherein said combination of compounds has  
5 increased efficacy and/or reduced toxicity, relative to any individual compound, in a greater portion of a population of patients having said pathology, comprising:

10 (a) correlating the efficacy and/or toxicity of a first compound with the presence of one or more genetic variations;

(b) correlating the efficacy and/or toxicity of a second compound with the presence of one or more genetic variations; and

15 (c) calculating the efficacy and/or toxicity of a combination of said first compound and said second compound on said population of patients;

wherein said combination is effective for at least one patient having said pathology. It is also contemplated herein that the combination of compounds can be effective  
20 for at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 50%, at least 75%, at least 90%, at least 95% or at least 98% of the total patient population.

A method of correlating efficacy or toxicity of  
25 a compound with one or more genetic variations as disclosed herein and as known in the art can be individually carried out for at least two compounds, and will typically be carried out for more than two

compounds. For example, such a method can be carried out for 3, 4, 5, 6, 7, 8, 9, or for 10 or more compounds. The efficacies or toxicities of combinations of such a plurality of compounds can then be calculated.

- 5 Also provided herein is an algorithm for determining the efficacy and/or toxicity of a combination of two or more compounds for a population of patients having a pathology, comprising the steps of:

- 10 (a) correlating the efficacy and/or toxicity of each of said two or more compounds with the presence of one or more genetic variations, preferably SNPs; and
- (b) combining the correlations of the efficacy and/or toxicity of each of said two or more
- 15 compounds with the presence of one or more genetic variations;

whereby the efficacy and/or toxicity of said combination of compounds for said population of patients is calculated.

- 20 The step of combining the correlations of the efficacy or toxicity of each of two or more compounds is carried out in accordance with the interaction of each compound with the other compounds. As disclosed herein, such interaction can be overlapping, independent,
- 25 partially overlapping, canceling or enhancing. Correlations so combined will result in a predicted efficacy or toxicity of one or more combinations of compounds in treating a population of patients with a

pathology, and will additionally result in predicted efficacies or toxicities of one or more combinations of compounds in one or more subpopulations of patients, where a subpopulation of patients is a group of defined  
5 as patients having the same genetic profile with respect to a pathology.

- In a further embodiment of the invention, a method is provided for treating one or more patients having a pathology with a combination of therapeutic  
10 compounds having increased efficacy and/or reduced toxicity, relative to any individual compound, in a greater portion of a population of patients having said pathology, comprising the steps of:
- 15 (a) correlating the efficacy and/or toxicity for each of two or more compounds with one or more genetic variations, preferably SNPs;
  - (b) calculating the efficacy and/or toxicity of administering said two or more compounds on said population of patients; and
  - 20 (c) administering said two or more compounds to said patients;

wherein said two or more compounds are effective for at least one patient having said pathology. It is also contemplated herein that the two or more compounds can be  
25 effective for at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 50%, at least 75%, at least 90%, at least 95% or at least 98% of the total patient population.

In a further embodiment, one or more compounds of a composition can be differently effective against one genetic variant than another. For example, a SNP-associated variant of a protease can arise that results in a glutamate changing to an alanine. Use of a protease inhibitor compound can result in the inhibition of the alanine SNP variant without inhibiting the glutamate SNP variant. Thus, it is within the scope of this invention that a compound can have a unique efficacy against each SNP variant of a target molecule.

However, it is also within the scope of the invention that a compound can have identical efficacies for one or more SNP variants of a target molecule. For example, a monoclonal antibody targeted against a protease can bind a region distant from the location of the SNP residue, thus the efficacy of the antibody will not be influenced by the presence of different SNP variants of the target protease.

Further, a compound can be equally effective against particular SNP variants, but differently effective against others. For example, a protease inhibitor, effective against a protease having three SNP variants, tryptophan, aspartate and asparagine, at a particular position can have the same efficacy against the aspartate and asparagine variants, but a different efficacy against the tryptophan variant.

The invention will now be described in greater detail by reference to the following non-limiting example. All U.S. patents and all publications mentioned

herein are incorporated in their entirety by reference thereto.

### Examples

#### Example I

#### 5 Five drugs with additive efficacies for five equally populated genotypes

A variety of drugs known to treat a pathology can be selected for analysis in order to determine a suitable combination of drugs for treating the pathology.

10 For example, drugs A, B, C, D and E which are all used to treat a particular pathology can be subjected to the following analysis. Each of the five drugs has a characteristic dose-response curve that is different for each of five different equally populated genotypes: \*1,

15 \*2, \*3, \*4 and \*5. Dose-response curves are shown for drugs A, B, C, D and E in figures 1, 2, 3, 4 and 5, respectively. Assuming each drug acts on a population or subpopulation in a manner that is independent from each of the other drugs, the efficacies of multiple drugs are

20 additive. For example, if drugs A and B act independently of each other with respect to the subpopulation of patients in genotype \*1, then the 10% of patients in genotype \*1 effectively treated by 0.1 mg of drug A, can be added to the 10% of patients in genotype

25 \*1 that are effectively treated by 0.1 mg of drug B, resulting in 20% of patients in genotype \*1 being effectively treated by a combination of 0.1 mg drug A and 0.1 mg drug B (see Table I).

In this manner, optimized combinations of drugs can be designed which treat a large percentage of the overall population of patients with a pathology, by adding together the percentages of each genotype treated by particular combinations of drugs at a particular dosages.

Once the percentage of a particular genotype exceeds 100%, no additional drugs or larger dosages are beneficial to that genotype. Thus, use of a combination of two drugs that are effective in treating the same genotype or genotypes, will have only a limited increased efficacy for the entire population. For example, if drugs D and E are combined at 0.1 mg each, the combination will exceed 100% effectiveness for genotype \*2, but will not greatly improve the effectiveness for genotypes \*3, \*4 and \*5 more than use of drug D or E alone, and therefore, will not provide a greatly increased efficacy for 60% of the total population relative to the use of drug D or E alone.

In contrast, if two drugs are effective in treating different genotypes, use of the two drugs in combination can have an additive increase in efficacy for the entire population. For example, drug B, at 0.1 mg, has 10% or greater efficacy for genotypes \*1, \*3 and \*4, while drug C, at 0.1 mg, has 10% or greater efficacy for genotypes \*2 and \*5, and therefore, the efficacy for the overall population is 31.3% for the combination of 0.1 mg drug B with 0.1 mg drug C.

In determining a suitable drug combination, optimized efficacy is combined with consideration of

minimal toxicity. As used in this example, drugs A, B, C and D have low toxicity, while drug E has high toxicity. In Table I, the efficacies of compounds A through E are provided for each of five genotypes at four different dosage levels, and numerous dose combinations (dose comb) are presented. The mean efficacy (Mean eff), toxicity (tox) and toxicity index (ME/T) are provided for a variety of dose combinations, which included either zero, .1 or 1 mg of each drug. However, many of these combinations also have a significant amount of toxicity. For example, the combination of 0.1 mg A, 0.1 mg B, 0.1 mg C, 0.1 mg D and 1 mg E, is effective for 61% of the total patient population, but this combination is also toxic for 50% of the total patient population. Knowledge of drug overlap and drug toxicity enables maximal coverage of the total patient population without significant toxicity, such as shown for the two drug combinations: 0.1 mg A, 0.1 mg B, 0.1 mg C and 0.1 mg D, which is effective for 49.3% of the total patient population while not being toxic; and 0.1 mg B, 0.1 mg C and 0.1 mg D, which is effective for 46.1% of the total patient population while not being toxic.

Without knowledge of the efficacy of a drug on the various genotypes in a population, the efficacy of each drug is only reported in terms of the efficacy for the overall population. Knowing only the efficacy for the overall population, the efficacy of a combination drugs cannot be determined. That is, two drugs may be combined, but lack of knowledge of the efficacy of a drug on the various genotypes in a population can yield any possible result varying from greatly increased efficacy to in zero increase in efficacy. Maximal increase in



efficacy of a combination of drugs is dependent on, for example, minimal drug overlap, which is determined by knowledge of the efficacy of each drug for each genotype.

11  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221  
2222  
2223  
2224  
2225  
2226  
2227  
2228  
2

TABLE I

Efficacy at Indicated Dose (%)		Efficacy at Indicated Dose (%)				
Drug A		Drug B				
Gene	0.1mg	1mg	10mg	50mg	0.1mg	1mg
1*	10	50	90	95	10	25
2*	3	10	50	80	2	5
3*	2	5	20	50	10	30
4*	0	0	0	50	90	60
5*	1	3	5	8	95	85
					97	90
					1	3
					3	10
					50	15
					90	20
					95	97

Efficacy at Indicated Dose (%)		Efficacy at Indicated Dose (%)				
Drug D		Drug E				
Gene	0.1mg	1mg	10mg	50mg	0.1mg	1mg
1*	50	90	95	97	1	3
2*	20	23	25	25	95	97
3*	0.1	1	10	50	10	30
4*	3	10	30	70	0.5	3
5*	1	1	1	1	2	10
					50	70

TABLE I (continued)

Cumulative efficacies for the selected representative dose combinations listed

Dose comb	.1/. 1	.1/. 1/1	.1.1 .1.1	.1.1 .1.1 .1	.1/0 /1	0/.1 /1	00.1 .1	000. 1.1	0.1. 1.1/ 0	00.1 .1.1 1	.1.1 .1.1 1	.1.1 .1.1 1.1	0.11 1.1 1.1	1111 1	0/.1 /0/1 /0	0/10/ .1/50 /0
Geno type																
1*	20	22	72	73	12	12	52	51	62	53	75	115	118	133	173	134
2*	5	35	55	150	33	32	50	115	52	145	152	155	185	188	195	75
3*	12	12.5	12.6	22.6	2.5	10.5	0.6	10.1	10.6	10.6	42.6	43.5	46	86	89	11
4*	50	51	54	54.5	1	51	4	3.5	54	4.5	57	64	66	106	106	166
5*	2	52	53	55	51	51	51	3	52	53	63	63	103	105	107	61
MEAN EFF	17.8	34.5	49.3	61	19.9	31.3	31.5	33.5	46.1	44.2	67.5	74.1	82.4	97.8	26.2	87.2
TOX	0	0	0	50	0	0	high	15	0	45	52	70	106	181	0	140.5
Tl-M E/T	high	high	high	1.22	high	high	high	2.23	high	0.98	1.3	1.06	0.78	0.54	high	0.62

### Example II

#### Two drugs with additive efficacies for two variably populated genotypes

In another example, knowledge of the efficacy of each drug can be used to prepare a drug combination even in the absence of knowledge of the exact distribution of different genotypes in the total patient population. In this example, two drugs, A and B have different efficacies for two different SNP variant groups, V1 and V2, of the total patient population. Once again, these drugs will be considered to be independent of one another, and therefore, the efficacies of the two drugs for either SNP variant are additive. Figures 6 and 7 show the dose-response relationships and toxicity thresholds for drugs A and B, respectively. Both drugs have a threshold toxicity of 30 mg, and for this example, the threshold toxicities are additive. For example, 20 mg of drug A in combination with 20 mg of drug B has the same toxicity as 40 mg of drug A or drug B. Thus, the maximum sum of drugs A and B that can be used in a combination while maintaining low toxicity is 30 mg.

Table II shows the efficacies of different drug dose amounts of drugs A and B, and of two combinations of A and B, for six different population distributions of SNP variants V1 and V2. Without knowledge of the exact distribution of the SNP variant groups in the total patient population, the combination with the highest mean response represents the combination effective for the maximum amount of the total patient population. The combination of 10 mg of drug A and 20 mg of drug B shows the highest mean response, which implies that this

combination is most likely to be the most effective combination for treatment of any unknown population distribution of SNP variant groups V1 and V2. The combination of 10 mg of drug A and 20 mg of drug B also  
5 shows the lowest variability (% CV), meaning that this combination has the most consistent efficacy over the entire spectrum of possible population distributions of SNP variant groups V1 and V2.

2025 RELEASE UNDER E.O. 14176

TABLE II

VARIANT		MONOTHERAPY (DRUG dose)						COMBINATIONS		
V1	V2	A <sub>10</sub>	A <sub>20</sub>	A <sub>30</sub>	B <sub>10</sub>	B <sub>20</sub>	B <sub>30</sub>	A <sub>10</sub> B <sub>20</sub>	A <sub>20</sub> B <sub>10</sub>	
100	0	50.0	66.7	75.0	16.7	28.6	37.5	78.6	83.4	
80	20	41.8	56.7	64.6	20.1	32.9	42.0	74.7	76.8	
60	40	33.6	46.7	54.2	23.3	37.2	46.5	70.8	70.0	
40	60	25.5	36.7	43.9	26.7	41.4	51.0	66.9	63.4	
20	80	17.3	26.7	33.5	30.0	45.7	55.5	63.0	56.7	
0	100	9.1	16.7	23.1	33.3	50.0	60.0	59.1	50.0	
MEAN		29.6	41.7	49.1	25.0	39.3	48.8	68.9	66.7	
RESPONSE		± 15.3	± 18.7	± 19.4	± 6.2	± 8.0	± 8.4	± 7.3	± 12.5	
CV (%)		51.7	44.8	39.5	24.8	20.4	17.2	10.6	18.7	

5

10

Although the invention has been described with reference to the disclosed embodiments, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly,  
5 the invention is limited only by the following claims.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25